The global high-throughput screening (HTS) market is projected to reach USD 21.69 billion by 2023 from USD 14.87 billion in 2018, at a CAGR of 7.8%. Factors such initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments are driving the growth of the HTS market. Emerging countries provide opportunities for players to expand their presence in the HTS market.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=134981950
In this report, the market is segmented on the basis of product & service, technology, application, end user, and region. On the basis of products & services, the global HTS market is segmented into reagents & assay kits, instruments, consumables & accessories, software, and services. The software segment is expected to register the highest CAGR during the forecast period. The growth of this segment is primarily attributed to the increasing automation of high-throughput screening and the availability of robust data management software tools, which enable researchers to develop systemic and process-oriented approaches toward HTS techniques.
On the basis of technology, the HTS market is segmented into cell-based assays, lab-on-a-chip (LOC), ultra-high-throughput screening (uHTS), label-free technology, and bioinformatics. The label-free technology segment is expected to register the highest CAGR during the forecast period. The major advantage offered by label-free technology is that it can help in the study of varied cell types and targets. Label-free assays also provide simple methods for studying complex biological pathways. The label-free technology is set to reduce drug failure caused by toxicity. These factors are likely to boost the growth of this technology market.
Based on application, the market is segmented into target identification & validation, primary & secondary screening, toxicology assessment, and other diseases (stem cells differentiation, protein synthesis, understanding/studying diseases, and food safety assessment). The primary & secondary screening segment is expected to register the highest CAGR during the forecast period. The increasing adoption of HTS for primary & secondary screening by HTS laboratories is the key factor contributing to the growth of this segment.
Based on end user, the HTS market is segmented into pharmaceutical and biotechnology companies, academic & government institutes, contract research organizations, and other end users (hospitals and food, agriculture & environmental industries). The contract research organizations segment is expected to register the highest CAGR during the forecast period owing to the increasing outsourcing of HTS services by many pharmaceutical & biotechnology companies.
Geographically, the HTS market in the APAC region is expected to register the highest CAGR during the forecast period. Factors such as increasing R&D spending, growing trend of outsourcing drug discovery services, growing public-private partnerships, and increasing government funding are driving the growth of this regional segment.
